Synthesis and Bioactivity of New Finasteride Conjugate
June 2011
in “
Bioorganic & Medicinal Chemistry Letters
”
TLDR New Finasteride conjugate improves prostate treatment and vital signs in rats.
The study aimed to develop a new Finasteride conjugate for the treatment of benign prostate hyperplasia (BPH). The new compound showed better inhibition of 5α-reductase activity in vitro and improved outcomes in vivo in a rat model with BPH. The rats in the Finasteride conjugate group also showed better vital signs than those in the Finasteride group. The results suggest that the Finasteride conjugate may have other functions on animals than Finasteride, possibly with improved immune response or reduced toxicity. Further research is needed to investigate the immune modulation activity of the Finasteride conjugate and compare it with Polimod.